Business
Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET
Webcast to be held Thursday, August 8th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. DALLAS--(BUSINESS WIRE)-- Lantern Pharma
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nWebcast to be held Thursday, August 8th, 4:30 p.m. ET, register for the webcast here, or at the link provided below.\n\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today announced that it will host its second quarter 2024 operating and financial results webcast on Thursday, August 8, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.\n\n\nManagement intends to discuss the operating and financial results for the second quarter ended June 30, 2024 and provide guidance on upcoming milestones, clinical trials and developments of the A.I. platform, RADR®. Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team.\n\n\nTo register for the webinar, please sign up at the Zoom webcast link provided in the link: Lantern Pharma Q2, 2024 earnings Zoom webcast registration link. A replay of the earnings call webcast will be available after the call on the investor relations section of the Company's website: ir.lanternpharma.com.\n\n\nAbout Lantern Pharma\n\n\nLantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 60 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 - 2.5 million per program.\n\n\nOur lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the ...